Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × SCLC × Immune Checkpoint Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 14 Carcinoma, Hepatocellular 7 Recurrence 5 Nasopharyngeal Carcinoma 5 Colorectal Neoplasms 5 Stomach Neoplasms 4 Neoplasm Metastasis 4 Esophageal Squamous Cell Carcinoma 4 Esophageal Neoplasms 4 Carcinoma, Renal Cell 4 Breast Neoplasms 4 Urinary Bladder Neoplasms 3 Melanoma 3 Colonic Neoplasms 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2 Neoplasms 2 Locally Advanced Rectal Cancer 2 Hyperthermia 2 Head and Neck Neoplasms 2 Cholangiocarcinoma 2 Biliary Tract Neoplasms 2 Advanced Refractory Solid Tumors 2 Advanced NSCLC 2 Urologic Neoplasms 1 Urologic Diseases 1 Urinary Bladder Diseases 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1

Interventions

apatinib 1 Platinum 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Etoposide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07110103 2026-02-27

JACKPOT38

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡